First Choice Research Centers Clinical Trials
First Choice Research Centers offer clinical trials for Alzheimer’s disease, Dementia, Parkinson’s disease, Epilepsy, and other neurological disorders.
First Choice Research Center 1 Clinical Trials
AZT-001 by AZTherapies, Inc.
This is a global 72-week study for subjects with evidence of early AD. The protocol is designed to determine whether ALZT-OP1 combination treatment (ALZT-OP1a + ALZT-OP1b) will slow down, arrests, or reverse cognitive and functional decline, in subjects with evidence of early stage Alzheimer's disease (AD). Patients must be between 55 and 79 years of age. Informant/study partner needed (compensation provided).
Longeveron (Allogenic Human Mesenchymal Stem Cells)
Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Longeveron Allogeneic Human Mesenchymal Stem Cell (LMSC) Infusion Versus Placebo in Patients with Alzheimer’s Disease. This is a 52-week phase I study for patients with early Alzheimer’s MMSE 18-24. Patients must be between 50 and 80 years of age. Informant/study partner needed (compensation provided).
YKP3089C025 by SK Life Science, Inc.
Placebo controlled 34-week clinical trial for patients with Primary Generalized Tonic Clonic Seizures to evaluate the safety and efficacy of Cenobamate as an adjunctive therapy.
TRIAD by Avanir
This is a 12-week clinical trial, investigating d6-DM/Q for the treatment of agitation in patients with dementia of the Alzheimer’s type. Patients must be between 50 and 90 years of age and have a MMSE score of 6 to 26. Informant/study partner needed (compensation provided).
First Choice Research Center 2 Clinical Trials
AD mission Study by Eisai
This is an oral BACE (beta-amyloid cleavage enzyme) inhibitor agent with a low side effect profile. Patients get a free amyloid PET CT during screening for this study. For MCI (mild cognitive impairment) and mild AD (Alzheimer’s disease) dementia patients. MMSE 24 and above. Top age is 85. Must be able to do an MRI brain. Informant/study partner needed.
Harmony Study by Acadia
This is a Nuplazid/Pimavanserin study for Dementia Patients with hallucinations and/or delusions ages 50-90. (Dementia-related Psychosis). ALL TYPES of Dementia are allowed and MRIs are not needed. Informant/study partner needed.
Periscope Study by Lilly
(LMDC trial) This is for Alzheimer’s disease and MCI patients. MMSE 22 and above. This is an infusion study with anti-TAU monoclonal Antibody. Patients will require TAU PET CT and MRI brain. Ages 60-85. Informant/study partner needed.
PRESENCE Study by Lilly
(HBEH trial). This is a Parkinson’s disease Dementia (PDD) Study. Ages 40-85. At least 2 years of Parkinson’s disease. Hoehn and Yahr Stages 1 to 4. This is a novel dopamine D1 receptor subtype (D1PAM) positive Dopamine allosteric modulator being tested to enhance cognition in PDD.
First Choice Research Center 32 Clinical Trials
This is a 1-year clinical trial, investigating Neridronic Acid in the form of an infusion for the treatment of Complex Regional Pain Syndrome. There will be 4 infusions over the course of 10 days, with the possibility of a second course of infusions at the 6-month mark. Patients must show CRPS symptoms for 2 years or less and have also failed at least 2 prior therapies.
This is a 6-month clinical trial, investigating Atogepant for the prevention of Migraines in patients with Episodic Migraine. Patients must be 18 to 80 years of age, have 4 to 14 probable migraine headache days per month and have a migraine onset age of less than 50.
TRIAD by Avanir
This is a 12-week clinical trial, investigating d6-DM/Q for the treatment of agitation in patients with dementia of the Alzheimer’s type. Patients must be between 50 and 90 years of age and have a MMSE score of 6 to 26.
RESTORE by Lundbeck
This is a 9-month clinical trial, investigating Droxidopa for Symptomatic Neurogenic Orthostatic Hypotension. Patients must have a documented drop of 20 mmHg in Systolic Blood Pressure, within 3 minutes of standing.
ALITHIOS by Novartis
This is a 5-year clinical trial, investigating the long-term safety and tolerability of Ofatumumab in patients with Relapsing Multiple Sclerosis. Patients must have participated in a Novartis MS trial using Ofatumumab as ALITHIOS is an open-label extension trial to its predecessor.
BRAIN by UCB
This is a 1-year clinical trial, investigating retention of patients using Brivaracetam for the treatment of epilepsy.
INSYTE by Acadia
This is a 3-year clinical trial, investigating the effectiveness of antipsychotic therapies and other treatment approaches in the management of Parkinson’s Disease Psychosis.
This is a 10-year clinical trial, investigating the necessary duration of monitoring in patients using Lemtrada for the treatment of Multiple Sclerosis.